PDCD1 and glioblastoma: GMB patients who received neoadjuvant pembrolizumab with continuous adjuvant therapy after surgery showed increased CD8+ cytotoxic lymphocytes, low PD-1 levels, and then better OS and PFS results compared to GBM patients who received adjuvant, postsurgical PD-1 blockade alone [46].